Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome

Annals of Neurology

Volumn 43, Issue 4, 1998, Pages 480-484

  Harper, C Michel ^a   Engel, Andrew G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; QUINIDINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MYASTHENIA GRAVIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACTION POTENTIALS; ADOLESCENT; ADULT; CHILD; ELECTRIC STIMULATION; FEMALE; HUMANS; MALE; MEDIAN NERVE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; PROSPECTIVE STUDIES; QUINIDINE; RECEPTORS, CHOLINERGIC; RECOMBINANT PROTEINS; SYNDROME;

EID: 0031749640     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430411     Document Type: Article

References (16)

1. Engel AG, Lambert EH, Mulder DM, et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 1982;11:553-569
2. Ohno K, Hutchinson DO, Milone M, et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the ε subunit. Proc Natl Acad Sci USA 1995;92:758-762
3. Sine SM, Ohno K, Bouzat C, et al. Mutation of the acetylcholine receptor α subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995;15: 229-239
4. Engel AG, Ohno K, Milone M, et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1996;5:1217-1227
5. Milone M, Wang H-L, Ohno K, et al. Slow-channel syndrome caused by enhanced activation, desensitization, and agonist binding affinity due to mutation in the M2 domain of the acetylcholine receptor alpha subunit. J Neurosci 1997;17:5651-5665
6. Gomez CM, Maselli R, Gammack J, et al. A beta-subunit mutation in the acetylcholine receptor gate causes severe slow-channel syndrome. Ann Neurol 1996;39:712-723
7. Croxen R, Newland C, Beeson D, et al. Mutations in different functional domains of the human muscle acetylcholine receptor α subunit in patients with the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1997;6:767-773
8. Engel AG. Myasthenic syndromes. In: Engel AG, Franzini-Armstrong C, eds. Myology: basic and clinical. 2nd ed. New York: McGraw-Hill, 1994:1798-1835
9. Harper CM. Neuromuscular transmission disorders in childhood. In: Jones RH, Bolton CF, Harper CM, eds. Pediatric clinical electromyography. Philadelphia: Lippincott-Raven, 1996: 353-385
10. Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 1996;712:179-189
11. Fukudome T, Ohno K, Brengman JM, Engel AG. Quinidine sulfate normalizes the open duration of slow channel congenital myasthenic syndrome acetylcholine receptor channels expressed in human embryonic kidney cells. Neurology 1997;48:A72 (Abstract)
12. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;45:799-807
13. Dyck PJ, Litchy WJ, Lehman KA, et al. Variables influencing neuropathy endpoints: the Rochester diabetic neuropathy study of healthy subjects. Neurology 1995;45:1115-1121
14. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-1571
15. Hermann RC. Repetitive stimulation studies. In: Daube JR, ed. Clinical neurophysiology. Philadelphia: FA Davis, 1996:237-244
16. Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996